Tff Pharmaceuticals (TFFP)

Company Profile

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally.

Company profile

Ticker

TFFP

Exchange

NASDAQ

Website

tffpharma.com

CEO

Glenn R. Mattes

Incorporated

Delaware

Location

Texas

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001733413

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

TFF Pharmaceuticals Australia Pty Ltd ...

IRS number

824344737

TFFP stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Entry into a Material Definitive Agreement

27 Dec 22

Entry into a Material Definitive Agreement

8 Dec 22

424B5

Prospectus supplement for primary offering

18 Nov 22

8-K

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

18 Nov 22

424B5

Prospectus supplement for primary offering

14 Nov 22

TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 22

8-K

Submission of Matters to a Vote of Security Holders

8 Nov 22

Transcripts

View all

TFFP

Earnings call transcript

2022 Q3

15 Nov 22

TFFP

Earnings call transcript

2022 Q2

12 Aug 22

TFFP

Earnings call transcript

2022 Q1

12 May 22

TFFP

Earnings call transcript

2021 Q4

25 Mar 22

TFFP

Earnings call transcript

2021 Q3

16 Nov 21

TFFP

Earnings call transcript

2021 Q2

13 Aug 21

TFFP

Earnings call transcript

2021 Q1

14 May 21

TFFP

Earnings call transcript

2020 Q4

11 Mar 21

TFFP

Earnings call transcript

2020 Q3

9 Nov 20

TFFP

Earnings call transcript

2020 Q2

13 Aug 20

Latest ownership filings

View all

Financial summary

Financial statements Chart TFFP financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	13.15 mm	13.15 mm	13.15 mm	13.15 mm	13.15 mm	13.15 mm
Cash burn (monthly)	2.58 mm	2.63 mm	2.43 mm	2.88 mm	2.46 mm	2.54 mm
Cash used (since last report)	10.90 mm	11.11 mm	10.25 mm	12.17 mm	10.38 mm	10.74 mm
Cash remaining	2.25 mm	2.04 mm	2.90 mm	977.76 k	2.76 mm	2.41 mm
Runway (months of cash)	0.9	0.8	1.2	0.3	1.1	0.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

TFFP institutional ownership history Ownership history

19.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	45	46	-2.2%
Opened positions	6	5	+20.0%
Closed positions	7	4	+75.0%
Increased positions	15	16	-6.3%
Reduced positions	10	8	+25.0%

13F shares	Current	Prev Q	Change
Total value	59.14 mm	65.91 mm	-10.3%
Total shares	7.11 mm	7.14 mm	-0.4%
Total puts	54.70 k	54.60 k	+0.2%
Total calls	42.90 k	117.30 k	-63.4%
Total put/call ratio	1.3	0.5	+173.9%

Largest owners	Shares	Value	Change
Lung Therapeutics	2.95 mm	$42.24 mm	0.0%
DRW Securities, L.L.C.	1.00 mm	$4.06 mm	NEW
Vanguard	868.43 k	$3.53 mm	0.0%
Sepio Capital	315.06 k	$1.28 mm	+222.5%
Gagnon Securities	284.83 k	$1.16 mm	+0.2%
Carlson Capital L P	275.00 k	$1.12 mm	-8.3%
BLK Blackrock	259.14 k	$1.05 mm	-0.7%
Geode Capital Management	188.33 k	$764.00 k	+1.6%
Princeton Capital Management	136.57 k	$554.00 k	+2.4%
UBS UBS Group AG - Registered Shares	97.61 k	$396.00 k	+5.9%

Largest transactions	Shares	Bought/sold	Change
DRW Securities, L.L.C.	1.00 mm	+1.00 mm	NEW
DRW Securities	0.00	-1.00 mm	EXIT
Sepio Capital	315.06 k	+217.36 k	+222.5%
Gsa Capital Partners	0.00	-93.68 k	EXIT
STT State Street	0.00	-69.93 k	EXIT
JPM JPMorgan Chase & Co.	0.00	-43.13 k	EXIT
Group One Trading	0.00	-37.27 k	EXIT
Carlson Capital L P	275.00 k	-25.00 k	-8.3%
Bridgeway Capital Management	58.70 k	-20.80 k	-26.2%
Virtu Financial	20.78 k	+20.78 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TFFP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Dec 22	Fletcher Aaron G.L.	Stock Options Common Stock	Grant	Acquire A	Yes	No	0.85	33,475	28.45 k	33,475
29 Dec 22	Robert S Mills	Stock Options Common Stock	Grant	Acquire A	No	No	0.85	33,475	28.45 k	33,475
29 Dec 22	Roberts Brandi	Stock Options Common Stock	Grant	Acquire A	No	No	0.85	20,968	17.82 k	20,968
29 Dec 22	Stephen Rocamboli	Stock Options Common Stock	Grant	Acquire A	No	No	0.85	33,475	28.45 k	33,475